Given the observations that comparable effects of MIAT silencing were witnessed in triple positive and triple negative breast cancer cells, whilst the expression levels of MIAT varied in relation to tumor grading by clinical stages, further studies using the MCF10 series representing different cancer stages should shed further light on the role of MIAT in breast cancer progression. This evidence concerns the gene MIAT and breast cancer.